{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:49:18Z","timestamp":1762148958710,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000263","name":"Parkinson Society Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008487","name":"Cure Parkinson\u2019s Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003136","name":"Edmond J. Safra Philanthropic Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.expneurol.2011.07.006","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T23:36:08Z","timestamp":1312328168000},"page":"195-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["5-HT1A receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: Bridging the gap between serotonergic and glutamatergic mechanisms"],"prefix":"10.1016","volume":"231","author":[{"given":"Philippe","family":"Huot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2011.07.006_bb0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0006-8993(95)01281-8","article-title":"Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study","volume":"706","author":"Arai","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0010","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s11064-006-9177-9","article-title":"Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats","volume":"31","author":"Ba","year":"2006","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00702-003-0094-7","article-title":"Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile","volume":"111","author":"Bartoszyk","year":"2004","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0020","first-page":"405","article-title":"In vitro uptake of dopamine in serotoninergic nerve terminals: a fluorescence histochemical study on vibratome sections of the rat cerebral cortex","volume":"19","author":"Berger","year":"1978","journal-title":"Adv. Biochem. Psychopharmacol."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0006-8993(78)90770-9","article-title":"Dopamine uptake in serotoninergic terminals in vitro: a valuable tool for the histochemical differentiation of catecholaminergic and serotoninergic terminals in rat cerebral structures","volume":"147","author":"Berger","year":"1978","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0030","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/jnr.21978","article-title":"Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats","volume":"87","author":"Bishop","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0035","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1471-4159.2005.03600.x","article-title":"The 5-HT(1A) receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors","volume":"96","author":"Calcagno","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF03004743","article-title":"Treatment of Parkinson's Disease with levodopa and amantadine used as single drugs and in combined therapy","volume":"143","author":"Callagham","year":"1974","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0045","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"issue":"Suppl. 2","key":"10.1016\/j.expneurol.2011.07.006_bb0050","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.parkreldis.2008.04.021","article-title":"Involvement of the serotonin system in L-dopa-induced dyskinesias","volume":"14","author":"Carta","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0079-6123(08)00922-9","article-title":"Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias","volume":"172","author":"Carta","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0925s41","article-title":"Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice","author":"Cenci","year":"2007","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0065","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1176\/appi.ajp.161.4.739","article-title":"Serotonin1A receptors at the axon initial segment of prefrontal pyramidal neurons in schizophrenia","volume":"161","author":"Cruz","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0070","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cne.1132","article-title":"Pyramidal cell axons show a local specialization for GABA and 5-HT inputs in monkey and human cerebral cortex","volume":"433","author":"DeFelipe","year":"2001","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0075","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.brainres.2007.05.005","article-title":"The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat","volume":"1158","author":"Dupre","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0080","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.neuropharm.2008.08.031","article-title":"Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat","volume":"55","author":"Dupre","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0085","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.expneurol.2011.02.012","article-title":"Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats","volume":"229","author":"Dupre","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0090","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/syn.20630","article-title":"The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats","volume":"63","author":"Eskow","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0095","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1523\/JNEUROSCI.5326-05.2006","article-title":"A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia","volume":"26","author":"Gardoni","year":"2006","journal-title":"J. Neurosci."},{"issue":"Suppl","key":"10.1016\/j.expneurol.2011.07.006_bb0100","first-page":"S553","article-title":"The role of serotonin in the action of L-dopa in an animal model of parkinsonism","volume":"29","author":"Gershanik","year":"1978","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0105","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/00002826-199310000-00004","article-title":"Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys","volume":"16","author":"Gomez-Mancilla","year":"1993","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0110","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/jnnp.57.8.903","article-title":"The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa","volume":"57","author":"Hely","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0115","article-title":"Regulation of cortical and striatal 5-HT(1A) receptors in the MPTP-lesioned macaque","author":"Huot","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0120","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1111\/j.1460-9568.2005.04169.x","article-title":"Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets","volume":"21","author":"Hurley","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0125","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0130","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1471-4159.2010.06776.x","article-title":"Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease","volume":"114","author":"Kobylecki","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0135","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.54.8.1589","article-title":"AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys","volume":"54","author":"Konitsiotis","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0140","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/j.1471-4159.2009.06556.x","article-title":"L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia","volume":"112","author":"Lindgren","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00213-008-1452-9","article-title":"Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats","volume":"204","author":"Marin","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0150","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/BF02272148","article-title":"5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors","volume":"28","author":"Mengod","year":"1996","journal-title":"Histochem. J."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0155","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00001756-200505120-00009","article-title":"8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease","volume":"16","author":"Mignon","year":"2005","journal-title":"Neuroreport"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0160","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(70)91987-2","article-title":"Treatment of Parkinsonism with L-dopa and amantadine","volume":"2","author":"Millac","year":"1970","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0165","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1046\/j.1471-4159.1999.721516.x","article-title":"Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats","volume":"72","author":"Miller","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0170","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.expneurol.2009.05.033","article-title":"Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model","volume":"219","author":"Munoz","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0175","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1471-4159.2011.07292.x","article-title":"Dopamine release from serotonergic nerve fibers is reduced in l-DOPA-induced dyskinesia","volume":"118","author":"Nevalainen","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0180","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.neuropharm.2011.05.021","article-title":"Role of the primary motor cortex in l-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation","volume":"61","author":"Ostock","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0185","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.neurobiolaging.2009.07.014","article-title":"Metabotropic glutamate receptor type 5 in levodopa-induced motor complications","volume":"32","author":"Ouattara","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0190","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Pahwa","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0195","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1471-1931(00)00022-7","article-title":"Organization of the basal ganglia: the importance of axonal collateralization","volume":"23","author":"Parent","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0200","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1532-5415.1975.tb00187.x","article-title":"Visual hallucinations and delirium during treatment with amantadine (Symmetrel)","volume":"23","author":"Postma","year":"1975","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0205","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling","volume":"330","author":"Rylander","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0210","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0215","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/mds.20345","article-title":"Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease","volume":"20","author":"Silverdale","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0220","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/syn.20739","article-title":"Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate","volume":"64","author":"Silverdale","year":"2010","journal-title":"Synapse"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/syn.890010103","article-title":"Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists","volume":"1","author":"Sprouse","year":"1987","journal-title":"Synapse"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0230","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0028-3908(88)90079-2","article-title":"Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: a comparative study with dorsal raphe neurons","volume":"27","author":"Sprouse","year":"1988","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0235","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson's disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02251134","article-title":"The metabolism of exogenous L-dopa in the brain: an immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain","volume":"3","author":"Tison","year":"1991","journal-title":"J. Neural. Transm. Park. Dis. Dement. Sect."},{"key":"10.1016\/j.expneurol.2011.07.006_bb0245","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01345246","article-title":"Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"14","author":"Verhagen Metman","year":"1998","journal-title":"Amino Acids"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0250","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2011.07.006_bb0255","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.nbd.2010.08.004","article-title":"Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia","volume":"40","author":"Zeng","year":"2010","journal-title":"Neurobiol. Dis."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488611002603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488611002603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:46:04Z","timestamp":1762148764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488611002603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0014488611002603"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2011.07.006","relation":{},"ISSN":["0014-4886"],"issn-type":[{"type":"print","value":"0014-4886"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"5-HT1A receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: Bridging the gap between serotonergic and glutamatergic mechanisms","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2011.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}